Contents:

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-3 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 Types of Lymphomas I-3 Hodgkin’s lymphoma I-3 Non-Hodgkin’s lymphoma I-3 II. Executive Summary 1. GLOBAL OUTLOOK II-1 Global Lymphoma Therapeutics Market to Surge II-1 Europe Leads the Global Lymphoma Therapeutics Market II-1 Lymphoma Incidence and Mortality Rates On the Rise II-1 Incidence of Hodgkins Lymphoma - High in West Asia II-2 Table 1: Age-Standardized Incidence Rates for Hodgkin’s Lymphoma in Select Countries Worldwide (2002) (includes corresponding Graph/Chart) II-2 Table 2: Age-Standardized Mortality Rates for Hodgkin’s Lymphoma in Select Countries Worldwide (2002) (includes corresponding Graph/Chart) II-3 Rituxan’s Dominance - A Major Hurdle to Other Emerging Drugs II-3 Huge Unmet Needs to Drive Product Innovation II-4 Radioimmunotherapy Drug Penetration Continues to Remain Lower II-4 Table 3: Monthly Cost of Select Non-Hodgkin’s Lymphoma Treatments (2009) II-4 Sales of Zevalin to Gain Momentum II-5 Combination Drugs - A Potential Winning Option for Manufacturers II-5 Existing Drugs for Lymphoma II-6 Select Approved Drugs In Lymphoma Treatment II-6 Rituxan - the Undisputed Leader in NHL Drugs II-6 Key Indications for Rituxan in the US II-7 Zevalin (Biogen Idec) II-7 Overview II-7 Administration II-8 Efficacy II-8 Bexxar (GlaxoSmithKline) II-9 Ribomustin®/Treanda® II-9 Pipeline Drugs for Lymphoma II-9 Select Pipeline Drugs In Lymphoma Treatment II-9 Select Vaccines In Pipeline for Lymphoma Treatment II-11 Pixantrone (Cell Therapeutics) II-11 Affinitor (Novartis) II-11 SGN-35 (Seattle Genetics) II-11 SAR3419 (ImmunoGen, Inc.) II-12 Overview of Treatment Options for NHL II-12 Chemotherapy II-12 Radiotherapy II-13 Antibody Therapy II-13 Stem Cell Transplants II-13 2. PRODUCT OVERVIEW II-14 Lymphomas II-14 Types of Lymphomas II-14 Hodgkin’s lymphoma II-14 Non-Hodgkin’s lymphoma II-14 Classification - Based on Type of Cells Involved II-14 Hodgkin’s Lymphomas II-15 Natural Killer (NK) and Mature T cell Neoplasms II-15 Mature B cell Neoplasms II-15 Classification - Based on Disease Progression II-16 Indolent Lymphomas II-16 Aggressive Lymphomas II-16 Background II-17 Signs and Symptoms II-17 Etiology and Risk Factors II-17 Immunological functions II-18 Infections II-18 Lifestyle Factors II-18 Diagnosis of Lymphoma II-18 Prognosis II-18 Treatment of Lymphoma II-19 3. DRUG APPROVALS II-20 Gloucester Obtains FDA Clearance for Istodax® in Treating CTCL II-20 Allos Obtains FDA Approval for FOLOTYN™ II-20 Spectrum Receives FDA Approval for Zevalin® Expanded Label II-20 Genzyme Receives European Commission Approval for Mozobil® II-21 Cephalon Obtains FDA Approval for TREANDA for Treating Indolent NHL II-21 GSK Receives European Approval for Atriance® II-22 4. RECENT INDUSTRY ACTIVITY II-23 Celgene to Acquire Gloucester Pharmaceuticals II-23 Scientists at Cornell Discover New Molecular Mechanism for Treating NHL II-23 CTI Seeks Orphan Drug Designation for Pixantrone in Europe II-24 FDAs ODAC Recommends Romidepsin’s Approval II-24 Seattle Genetics Completes Enrollment for Brentuximab Vedotin II-24 InNexus Biotechnology to Initiate Business Development for DXL625 II-25 Allos Therapeutics Introduces focusonptcl.com II-25 InNexus Inks Letter of Intent with Genhelix II-25 Pfizer Acquires Wyeth II-25 LLS and FORMA Join Hands to Accelerate Development of New Therapies II-26 Biovest and idis Ink Partnership Deal for Distribution of BiovaxID® II-26 SymBio Pharmaceuticals Signs a License Agreement with Eisai II-27 Seattle Genetics Receives Fast Track Designation from FDA for SGN-35 II-27 Spectrum Acquires ZEVALIN® from RIT Oncology II-27 EpiCept Announces Crinobulin as Generic Name for EPC2407 II-27 CTI Enters Into a Joint Venture with Spectrum Pharmaceuticals II-28 Allos Receives Orphan Drug Designation for Pralatrexate from FDA II-28 Takeda Acquires Millennium Pharmaceuticals II-28 5. FOCUS ON SELECT GLOBAL PLAYERS II-29 Allos Therapeutics, Inc. (US) II-29 Astellas Pharma US, Inc. (US) II-29 Biogen Idec (US) II-29 Biolex Therapeutics, Inc. (US) II-30 Biovest International, Inc. (US) II-30 Cell Therapeutics, Inc. (US) II-31 Cephalon, Inc. (US) II-31 Chugai Pharmaceutical Co., Ltd. (Japan) II-31 Cyclacel Pharmaceuticals, Inc. (US) II-32 Eisai, Ltd. (Japan) II-32 EpiCept Corp. (US) II-33 F. Hoffmann-la Roche Ltd. (Switzerland) II-33 Genentech, Inc. (US) II-33 Genmab (Denmark) II-34 Genitope Corp. (US) II-34 Genzyme Corporation (US) II-35 GlaxoSmithKline, Plc. (UK) II-35 Hana Biosciences, Inc. (US) II-35 ImmunoGen, Inc. (US) II-36 InNexus Biotechnology, Inc. (Canada) II-36 Millennium Pharmaceuticals, Inc. (US) II-36 6. GLOBAL MARKET PERSPECTIVE II-38 Table 4: World Recent Past, Current & Future Analysis for Lymphoma Drugs Market by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart) II-38 Table 5: World 10-year Perspective for Lymphoma Drugs Market by Geographic Region - Percentage Breakdown of Value Sales for US, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart) II-39 III. MARKET 1. UNITED STATES III-1 A.Market Analysis III-1 Rising Incidence of Lymphomas to Fuel Market Growth III-1 Mortality Rate Slips III-1 Lymphomas - The Third Leading Cause of Cancer in Children III-1 Table 6: Percentage Breakdown of Cancer Incidence in US Children by Type (2006) (includes corresponding Graph/Chart) III-2 White Children - Most Susceptible to Lymphomas III-2 Table 7: Incidence of Lymphoma in US Children in 2006 (includes corresponding Graph/Chart) III-2 Lymphoma Fact Sheet III-3 Incidence Rate Rises in Afro-Americans III-3 Table 8: US Lymphoma Incidence Rates in Men of All Ages by Race: 2002-2006 (includes corresponding Graph/Chart) III-3 Table 9: US Lymphoma Incidence Rates in Women of All Ages by Race: 2002-2006 (includes corresponding Graph/Chart) III-4 Table 10: US Lymphoma Mortality Rates in Men of All Ages by Race: 2002-2006 (includes corresponding Graph/Chart) III-4 Table 11: US Lymphoma Mortality Rates in Women of All Ages by Race: 2002-2006 (includes corresponding Graph/Chart) III-5 Select Players in the Region III-5 New Drug Approvals III-11 Strategic Corporate Developments III-13 B.Market Analytics III-18 Table 12: US Recent Past, Current & Future Analysis for Lymphoma Drugs Market with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart) III-18 2. EUROPE III-19 A.Market Analysis III-19 Europe - The Largest Market for Lymphoma Therapeutics Worldwide III-19 Incidence of NHL Continues to Climb III-19 Table 13: Annual Incidence of Non-Hodgkin’s Lymphomas in Europe: 2003-2010 (includes corresponding Graph/Chart) III-19 Table 14: Incidence Rates of Key Types of Non-Hodgkin’s Lymphomas in Europe:2006 (includes corresponding Graph/Chart) III-20 Immunotherapeutic Drugs Dominate the Market III-20 New Drugs to Transform Non-Hodgkins Lymphoma Market III-21 Restraining Forces Loom Large Over New Drugs III-21 An Overview of Lymphomas in United Kingdom III-21 Table 15: Hodgkin’s Lymphoma Incidence in UK (2006) III-22 Table 16: Hodgkin’s Lymphoma Incidence in UK by Sex (2006): Percentage Breakdown by Age Group (includes corresponding Graph/Chart) III-22 Select Players in the Region III-22 New Drug Approvals III-24 Strategic Corporate Developments III-25 B.Market Analytics III-26 Table 17: European Recent Past, Current & Future Analysis for Lymphoma Drugs Market with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart) III-26 3. REST OF WORLD III-27 A.Market Analysis III-27 Rest of World Lymphoma Therapeutics Market to Witness Rapid Growth III-27 Select Players in the Region III-27 Strategic Corporate Developments III-28 B.Market Analytics III-29 Table 18: Rest of World Recent Past, Current & Future Analysis for Lymphoma Drugs Market with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart) III-29 IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 93 (including Divisions/Subsidiaries - 104) --------- Region/Country Players --------- The United States 71 Canada 6 Japan 7 Europe 17 France 4 Germany 5 The United Kingdom 3 Spain 1 Rest of Europe 4 Asia-Pacific (Excluding Japan) 3

Companies Mentioned

- Allos Therapeutics, Inc. (US) - Astellas Pharma US, Inc. (US) - Biogen Idec (US) - Biolex Therapeutics, Inc. (US) - Biovest International, Inc. (US) - Cell Therapeutics, Inc. (US) - Cephalon, Inc. (US) - Chugai Pharmaceutical Co., Ltd. (Japan) - Cyclacel Pharmaceuticals, Inc. (US) - Eisai, Ltd. (Japan) - EpiCept Corp. (US) - F. Hoffmann-la Roche Ltd. (Switzerland) - Genentech, Inc. (US) - Genmab (Denmark) - Genitope Corp. (US) - Genzyme Corporation (US) - GlaxoSmithKline, Plc. (UK) - Hana Biosciences, Inc. (US) - ImmunoGen, Inc. (US) - InNexus Biotechnology, Inc. (Canada) - Millennium Pharmaceuticals, Inc. (US)